Misplaced Pages

Alogliptin: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 23:23, 10 October 2011 editThe chemistds (talk | contribs)Extended confirmed users5,761 edits added CSID, (Std)InChI & (Std)InChIKey← Previous edit Latest revision as of 22:13, 31 March 2024 edit undoAnomieBOT (talk | contribs)Bots6,568,436 editsm Dating maintenance tags: {{Better source needed}} 
(107 intermediate revisions by 52 users not shown)
Line 1: Line 1:
{{Short description|Anti-diabetic drug}}
{{Drugbox {{Drugbox
| Verifiedfields = changed
| Watchedfields = changed | Watchedfields = changed
| verifiedrevid = 437181578 | verifiedrevid = 454952697
⚫ | IUPAC_name = 2-({6--3-methyl-2,4-dioxo-<br>3,4-dihydropyrimidin-1(2''H'')-yl}methyl)benzonitrile
| image = Alogliptin.svg | image = Alogliptin.svg
| alt =


<!--Clinical data--> <!--Clinical data-->
| tradename = | pronounce =
| tradename = Nesina, Vipidia<br />Kazano, Vipidomet (with ])<br />Oseni, Incresync (with ])
⚫ | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| Drugs.com = {{drugs.com|monograph|alogliptin}}
| pregnancy_US = <!-- A / B / C / D / X -->
| MedlinePlus = a613026
| licence_EU = yes
| DailyMedID = Alogliptin
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->
⚫ | pregnancy_AU = B3
| pregnancy_AU_comment =
| pregnancy_US = B
| pregnancy_US_comment =
| pregnancy_category = | pregnancy_category =
⚫ | routes_of_administration = ]
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
⚫ | ATC_prefix = A10
⚫ | ATC_suffix = BH04

| legal_AU = S4
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US = Rx-only
| legal_status = | legal_EU = Rx-only
| legal_status = Rx-only
⚫ | routes_of_administration = Oral


<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
| bioavailability = | bioavailability = 100%
| protein_bound = | protein_bound = 20%
| metabolism = | metabolism = Limited, ] (]- and ]-mediated)
| elimination_half-life = | elimination_half-life = 12–21 hours
| excretion = | excretion = ] (major)<ref name=AACE/> and fecal (minor)


<!--Identifiers--> <!--Identifiers-->
| IUPHAR_ligand = 6319
⚫ | CAS_number = 850649-62-6
| CAS_number_Ref = {{cascite|correct|CAS}}
⚫ | ATC_prefix = A10
⚫ | CAS_number = 850649-61-5
⚫ | ATC_suffix = BH04
| PubChem = 11450633 | PubChem = 11450633
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = | DrugBank =
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 72323
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = JHC049LO86 | UNII = JHC049LO86
Line 37: Line 53:
| ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 376359 | ChEMBL = 376359
| synonyms = SYR-322

| index2_label = benzoate
| CAS_number2_Ref = {{cascite|correct|CAS}}
| CAS_number2 = 850649-62-6
| UNII2_Ref = {{fdacite|correct|FDA}}
| UNII2 = EEN99869SC


<!--Chemical data--> <!--Chemical data-->
⚫ | IUPAC_name = 2-({6--3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2''H'')-yl}methyl)benzonitrile
| C=18 | H=21 | N=5 | O=2 | C=18 | H=21 | N=5 | O=2
| molecular_weight = 339.39 g/mol
| smiles = N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC(N)C2 | smiles = N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC(N)C2
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9625485 | ChemSpiderID = 9625485
| InChI = 1/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
⚫ | InChIKey = ZSBOMTDTBDDKMP-OAHLLOKOBG
| StdInChI = 1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1 | StdInChI = 1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZSBOMTDTBDDKMP-OAHLLOKOSA-N
⚫ | StdInChIKey = ZSBOMTDTBDDKMP-OAHLLOKOSA-N
}} }}
'''Alogliptin''' (codenamed '''SYR-322''') is an investigational ] in the ] class,<ref name="pmid17441705">{{cite journal |author=Feng J, Zhang Z, Wallace MB, ''et al.'' |title=Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV |journal=] |volume=50 |issue=10 |pages=2297–300 |year=2007 |pmid=17441705 |doi=10.1021/jm070104l}}</ref> being developed by ]. In January 2008, Takeda submitted a ] for alogliptin to the U.S. ], after positive results from ] ]s.<ref>{{cite press release | url = http://www.takeda.com/press/article_28864.html | title = Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | date = January 4, 2008 | accessdate = 2008-01-09 | publisher = ]}}</ref> However, the FDA submission was suspended or withdrawn in June 2009 needing more data.<ref>{{cite news|url=http://www.genengnews.com/news/bnitem.aspx?name=55661199&source=genwire|title=GEN News Highlights: Takeda Pulls MAA for Type 2 Diabetes Therapy|date=4 June 2009|publisher=Genetic Engineering and Biotechnology News}}</ref>


'''Alogliptin''', sold under the brand names '''Nesina''' and '''Vipidia''',<ref name=takedapr28864/><ref name=EMA2018>{{cite web |title=Vipidia |url=https://www.ema.europa.eu/documents/overview/vipidia-epar-summary-public_en.pdf |publisher=European Medicines Agency |access-date=31 March 2024 |archive-url=https://web.archive.org/web/20181101160452/https://www.ema.europa.eu/documents/overview/vipidia-epar-summary-public_en.pdf |archive-date=1 November 2018 |url-status=dead }}</ref> is an oral ] in the ] (gliptin) class.<ref name=pmid17441705/> Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity.<ref name=AACE/> Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.<ref name=AACE>{{cite web |url=https://www.aace.com/files/algorithm-07-11-2013.pdf |title=www.aace.com |archive-url=https://web.archive.org/web/20181101160532/https://www.aace.com/files/algorithm-07-11-2013.pdf |archive-date=2018-11-01 |url-status=dead }}</ref>
⚫ ==References==

⚫ {{reflist}}
In April 2016, the U.S. ] (FDA) added a warning about increased risk of ].<ref name=FDA2016>{{cite web|title= FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin |url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes |website=U.S. Food and Drug Administration (FDA) |access-date=16 March 2018 }}</ref> It was developed by Syrrx, a company which was acquired by ] in 2005.<ref>{{Cite web|url=http://www.utsandiego.com/uniontrib/20050208/news_1b8syrrx.html|title = The San Diego Union-Tribune - San Diego, California & National News}}</ref> In 2020, it was the 295th most commonly prescribed medication in the United States, with more than 1{{nbsp}}million prescriptions.<ref>{{cite web | title = The Top 300 of 2020 | url = https://clincalc.com/DrugStats/Top300Drugs.aspx | website = ClinCalc | access-date = 7 October 2022}}</ref><ref>{{cite web | title = Alogliptin - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Alogliptin | access-date = 7 October 2022}}</ref>

==Medical uses==
Alogliptin is a ] (DDP-4) that decreases blood sugar levels similar to other DPP-4 inhibitors.<ref>{{cite journal | vauthors = Saisho Y | title = Alogliptin benzoate for management of type 2 diabetes | journal = Vascular Health and Risk Management | volume = 11 | pages = 229–243 | date = 2015 | pmid = 25914541 | pmc = 4401208 | doi = 10.2147/VHRM.S68564 | doi-access = free }}</ref>

==Side effects==
Adverse events include ],<ref name=seino2011/><ref name=kutoh2012/><ref name=bosi2011/> ] (itching),<ref name=EMA2018/> ], headache, and ].<ref name=FDA_Nesina/> It may also cause joint pain that can be severe and disabling.<ref>{{cite web|title=DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain|url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain|website=U.S. Food and Drug Administration (FDA)|access-date=1 September 2015|date=2015-08-28}}</ref> Like other DDP-4 inhibitors, alogliptin is weight-neutral.<ref name=AACE/>

A 2014 letter to the editor claimed alogliptin is not associated with increased risk of cardiovascular events.<ref>{{cite journal | vauthors = White WB, Zannad F | title = Saxagliptin, alogliptin, and cardiovascular outcomes | journal = The New England Journal of Medicine | volume = 370 | issue = 5 | pages = 484 | date = January 2014 | pmid = 24482824 | doi = 10.1056/NEJMc1313880 }}</ref>{{better source needed|reason=This is a letter to the editor.|date=March 2024}} In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of ].<ref name=FDA2016/>

==Market access==
]
In December 2007, Takeda submitted a ] (NDA) for alogliptin to the ] (FDA),<ref name=grogan2012/> after positive results from ].<ref name=takedapr28864/> In September 2008, the company also filed for approval in Japan,<ref name=geneng2009/> winning approval in April 2010.<ref name=grogan2012/> The company also filed a ] elsewhere outside the United States, which was withdrawn in June 2009 needing more data.<ref name=geneng2009/> The first NDA failed to gain approval and was followed by a pair of NDAs (one for alogliptin and a second for a combination of alogliptin and ]) in July 2011.<ref name=grogan2012/> In 2012, Takeda received a negative response from the FDA on both of these NDAs, citing a need for additional data.<ref name=grogan2012/>

In 2013, the FDA approved the drug in three formulations: as a stand-alone with the brand-name Nesina,<ref name="FDA_Nesina">{{cite web |title=Highlights of Prescribing Information: Nesina |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf |publisher=US Food and Drug Administration |access-date=31 March 2024}}</ref> combined with ] using the name Kazano,<ref name="FDA_Kazano">{{cite web |title=Highlights of Prescribing Information: Kazano |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203414s000lbl.pdf |publisher=US Food and Drug Administration |access-date=31 March 2024}}</ref> and when combined with ] as Oseni.<ref name="FDA_Oseni">{{cite web |title=Highlights of Prescribing Information: Oseni |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022426s005lbl.pdf |publisher=US Food and Drug Administration |access-date=31 March 2024}}</ref>{{clear}}

⚫ == References ==
⚫ {{reflist|refs=

<ref name=geneng2009>{{cite news |url=http://www.genengnews.com/news/bnitem.aspx?name=55661199 |title=GEN News Highlights: Takeda Pulls MAA for Type 2 Diabetes Therapy |date=June 4, 2009 |publisher=]}}</ref>

<ref name=grogan2012>{{Citation | vauthors = Grogan K |date=April 26, 2012 |title=FDA wants yet more data on Takeda diabetes drug alogliptin |periodical=] |at=PharmaTimes online | publisher=PharmaTimes |access-date=April 26, 2012 |url=http://www.pharmatimes.com/Article/12-04-26/FDA_wants_yet_more_data_on_Takeda_diabetes_drug_alogliptin.aspx }}</ref>

<ref name=pmid17441705>{{cite journal | vauthors = Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL | display-authors = 6 | title = Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV | journal = Journal of Medicinal Chemistry | volume = 50 | issue = 10 | pages = 2297–2300 | date = May 2007 | pmid = 17441705 | doi = 10.1021/jm070104l }}</ref>

<ref name=seino2011>{{cite journal | vauthors = Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K | title = Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study | journal = Current Medical Research and Opinion | volume = 27 | issue = 9 | pages = 1781–1792 | date = September 2011 | pmid = 21806314 | doi = 10.1185/03007995.2011.599371 | s2cid = 24082863 }}</ref>

<ref name=kutoh2012>{{cite journal | vauthors = Kutoh E, Ukai Y | title = Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial | journal = Endocrine | volume = 41 | issue = 3 | pages = 435–441 | date = June 2012 | pmid = 22249941 | doi = 10.1007/s12020-012-9596-0 | s2cid = 45948727 | publication-date = January 17, 2012 }}</ref>

<ref name=bosi2011>{{cite journal | vauthors = Bosi E, Ellis GC, Wilson CA, Fleck PR | title = Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study | journal = Diabetes, Obesity & Metabolism | volume = 13 | issue = 12 | pages = 1088–1096 | date = December 2011 | pmid = 21733058 | doi = 10.1111/j.1463-1326.2011.01463.x | s2cid = 1092260 | publication-date = October 27, 2011 }}</ref>

<ref name=takedapr28864>{{cite press release |url=https://www.takeda.com/en-us/newsroom/news-releases/2008/takeda-submits-new-drug-application-for-alogliptin-syr-322-in-the-u.s/ |title=Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. |date=January 3, 2008 |access-date=March 11, 2021 |publisher=] }}</ref>
}}

== External links ==
* {{Commons category-inline}}
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/rn/850649-61-5 | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Alogliptin }}


{{Oral hypoglycemics}} {{Oral hypoglycemics}}
{{Portal bar | Medicine}}


] ]
Line 61: Line 122:
] ]
] ]
]

]

]
{{gastrointestinal-drug-stub}}

Latest revision as of 22:13, 31 March 2024

Anti-diabetic drug Pharmaceutical compound
Alogliptin
Clinical data
Trade namesNesina, Vipidia
Kazano, Vipidomet (with metformin)
Oseni, Incresync (with pioglitazone)
Other namesSYR-322
AHFS/Drugs.comMonograph
MedlinePlusa613026
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability100%
Protein binding20%
MetabolismLimited, liver (CYP2D6- and 3A4-mediated)
Elimination half-life12–21 hours
ExcretionKidney (major) and fecal (minor)
Identifiers
IUPAC name
  • 2-({6--3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.256.501 Edit this at Wikidata
Chemical and physical data
FormulaC18H21N5O2
Molar mass339.399 g·mol
3D model (JSmol)
SMILES
  • N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC(N)C2
InChI
  • InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
  • Key:ZSBOMTDTBDDKMP-OAHLLOKOSA-N
  (what is this?)  (verify)

Alogliptin, sold under the brand names Nesina and Vipidia, is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.

In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of heart failure. It was developed by Syrrx, a company which was acquired by Takeda Pharmaceutical Company in 2005. In 2020, it was the 295th most commonly prescribed medication in the United States, with more than 1 million prescriptions.

Medical uses

Alogliptin is a dipeptidyl peptidase-4 inhibitor (DDP-4) that decreases blood sugar levels similar to other DPP-4 inhibitors.

Side effects

Adverse events include hypoglycemia, pruritis (itching), nasopharyngitis, headache, and upper respiratory tract infection. It may also cause joint pain that can be severe and disabling. Like other DDP-4 inhibitors, alogliptin is weight-neutral.

A 2014 letter to the editor claimed alogliptin is not associated with increased risk of cardiovascular events. In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of heart failure.

Market access

Alogliptin tablets sales in mainland China. Specification is 25 mg × 10 tablets.

In December 2007, Takeda submitted a New Drug Application (NDA) for alogliptin to the United States Food and Drug Administration (FDA), after positive results from Phase III clinical trials. In September 2008, the company also filed for approval in Japan, winning approval in April 2010. The company also filed a Marketing Authorization Application elsewhere outside the United States, which was withdrawn in June 2009 needing more data. The first NDA failed to gain approval and was followed by a pair of NDAs (one for alogliptin and a second for a combination of alogliptin and pioglitazone) in July 2011. In 2012, Takeda received a negative response from the FDA on both of these NDAs, citing a need for additional data.

In 2013, the FDA approved the drug in three formulations: as a stand-alone with the brand-name Nesina, combined with metformin using the name Kazano, and when combined with pioglitazone as Oseni.

References

  1. ^ "www.aace.com" (PDF). Archived from the original (PDF) on 2018-11-01.
  2. ^ "Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S." (Press release). Takeda Pharmaceutical Company. January 3, 2008. Retrieved March 11, 2021.
  3. ^ "Vipidia" (PDF). European Medicines Agency. Archived from the original (PDF) on 1 November 2018. Retrieved 31 March 2024.
  4. Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, et al. (May 2007). "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV". Journal of Medicinal Chemistry. 50 (10): 2297–2300. doi:10.1021/jm070104l. PMID 17441705.
  5. ^ "FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin". U.S. Food and Drug Administration (FDA). Retrieved 16 March 2018.
  6. "The San Diego Union-Tribune - San Diego, California & National News".
  7. "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  8. "Alogliptin - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  9. Saisho Y (2015). "Alogliptin benzoate for management of type 2 diabetes". Vascular Health and Risk Management. 11: 229–243. doi:10.2147/VHRM.S68564. PMC 4401208. PMID 25914541.
  10. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K (September 2011). "Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study". Current Medical Research and Opinion. 27 (9): 1781–1792. doi:10.1185/03007995.2011.599371. PMID 21806314. S2CID 24082863.
  11. Kutoh E, Ukai Y (June 2012). "Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial". Endocrine. 41 (3) (published January 17, 2012): 435–441. doi:10.1007/s12020-012-9596-0. PMID 22249941. S2CID 45948727.
  12. Bosi E, Ellis GC, Wilson CA, Fleck PR (December 2011). "Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study". Diabetes, Obesity & Metabolism. 13 (12) (published October 27, 2011): 1088–1096. doi:10.1111/j.1463-1326.2011.01463.x. PMID 21733058. S2CID 1092260.
  13. ^ "Highlights of Prescribing Information: Nesina" (PDF). US Food and Drug Administration. Retrieved 31 March 2024.
  14. "DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain". U.S. Food and Drug Administration (FDA). 2015-08-28. Retrieved 1 September 2015.
  15. White WB, Zannad F (January 2014). "Saxagliptin, alogliptin, and cardiovascular outcomes". The New England Journal of Medicine. 370 (5): 484. doi:10.1056/NEJMc1313880. PMID 24482824.
  16. ^ Grogan K (April 26, 2012), "FDA wants yet more data on Takeda diabetes drug alogliptin", PharmaTimes, PharmaTimes, PharmaTimes online, retrieved April 26, 2012
  17. ^ "GEN News Highlights: Takeda Pulls MAA for Type 2 Diabetes Therapy". Genetic Engineering & Biotechnology News. June 4, 2009.
  18. "Highlights of Prescribing Information: Kazano" (PDF). US Food and Drug Administration. Retrieved 31 March 2024.
  19. "Highlights of Prescribing Information: Oseni" (PDF). US Food and Drug Administration. Retrieved 31 March 2024.

External links

  • Media related to Alogliptin at Wikimedia Commons
  • "Alogliptin". Drug Information Portal. U.S. National Library of Medicine.
Oral diabetes medication, insulins and insulin analogs, and other drugs used in diabetes (A10)
Insulins / insulin analogs
fast-acting
short-acting
long-acting
ultra-long-acting
inhalable
  • Exubera
  • Afrezza
Non-insulins
Insulin sensitizers
Biguanides
TZDs/"glitazones" (PPAR)
Dual PPAR agonists
Amylin analogs and DACRAs
Secretagogues
KATP
Sulfonylureas
Meglitinides/"glinides"
GLP-1 receptor agonists
GLP1 poly-agonist peptides
DPP-4 inhibitors/"gliptins"
Other
Aldose reductase inhibitors
Alpha-glucosidase inhibitors
SGLT2 inhibitors/"gliflozins"
Other
Combinations
Portal: Categories: